Finance

Lists
UCB:EBR
UCB SA
€222.90
+2.72%
(+5.90) 1D
Jul 31, 5:35:02 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for UCB...
Open
€220.20
High
€228.40
Low
€220.00
Mkt. cap
42.63B
Avg. vol.
222.22K
Volume
497.58K
Dividend
0.46%
Quarterly dividend
€0.25
Ex-dividend date
May 4, 2026
P/E ratio
27.78
52-wk high
€289.50
52-wk low
€181.15
EPS
€8.02
Shares outstanding
194.51M
No. of employees
10K
Open
€220.20
High
€228.40
Low
€220.00
Mkt. cap
42.63B
Avg. vol.
222.22K
Volume
497.58K
Dividend
0.46%
Quarterly dividend
€0.25
Ex-dividend date
May 4, 2026
P/E ratio
27.78
52-wk high
€289.50
52-wk low
€181.15
EPS
€8.02
Shares outstanding
194.51M
No. of employees
10K
News stories
From sources across the web
Profile
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology. Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
About UCB SA
CEOJean-Christophe Tellier
Employees9.76K
FoundedJan 18, 1928
Headquarters-
SectorPharmaceutical industry
Websiteucb.com
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
Jun 2025
Sep 2025
Dec 2025
Jun 2026
Revenue
1.74B
2.13B
2.13B
-
Cost of goods sold
461.00M
534.00M
534.00M
-
Cost of revenue
461.00M
534.00M
534.00M
-
Research and development expenses
430.00M
481.00M
481.00M
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
639.00M
735.50M
735.50M
-
Operating expense
935.50M
946.50M
946.50M
-
Total operating expenses
1.40B
1.48B
1.48B
-
Operating income
347.00M
646.50M
646.50M
-
Other non operating income
-
36.00M
36.00M
-
EBT including unusual items
296.50M
614.50M
614.50M
-
EBT excluding unusual items
308.00M
622.50M
622.50M
-
Income tax expense
59.00M
73.00M
73.00M
-
Effective tax rate
19.90%
11.88%
11.88%
-
Other operating expenses
-133.50M
-270.00M
-270.00M
-
Net income
237.50M
541.50M
541.50M
-
Net profit margin
13.62%
25.46%
25.46%
-
Earnings per share
-
-
-
-
Interest and investment income
40.00M
-
-
-
Interest expense
-21.50M
-17.50M
-58.00M
-
Net interest expenses
18.50M
-58.00M
-58.00M
-
Depreciation and amortization charges
-
-
-
-
EBITDA
503.50M
803.50M
803.50M
-
Gain or loss from assets sale
-
1.00M
1.00M
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps